Q2 2026 revenue grew 20% year-over-year to $990M, driven by rare disease portfolio strength and Amicus integration. Full-year guidance for revenue, VOXZOGO, and Non-GAAP EPS was raised, with significant cost synergies and accelerated growth expected from the Amicus acquisition.Original document: Bi…
Q2 2026 revenue grew 20% year-over-year to $990M, driven by rare disease portfolio strength and Amicus integration. Full-year guidance for revenue, VOXZOGO, and Non-GAAP EPS was raised, with significant cost synergies and accelerated growth expected from the Amicus acquisition.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
